Novartis Wins FDA Approval of Kisqali for Early Breast Cancer - Eli Lilly ( NYSE:LLY ) , Novartis ( NYSE:NVS )
Novartis NVS announced that the FDA has approved breast cancer drug Kisqali ( ribociclib ) for a broader population.
| Ticker |
Sentiment |
Impact |
|
LLY
|
Neutral
|
12 %
|
|
PFE
|
Neutral
|
6 %
|
